Ursodeoxycholic Acid in C. Difficile Infection (NCT05526807) | Clinical Trial Compass
TerminatedNot Applicable
Ursodeoxycholic Acid in C. Difficile Infection
Stopped: Slow recruitment
United Kingdom6 participantsStarted 2019-05-08
Plain-language summary
The primary objective of the study is to assess tolerability and adherence to treatment with ursodeoxycholic acid
Who can participate
Age range18 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* Completion of a course of antibiotic treatment for C. difficile infection within the previous 7 days
Exclusion Criteria:
* • Pregnant or Breast-feeding
* Gall bladder inflammation
* Frequent episodes of biliary colic
* Occlusion of the common bile duct or cystic duct
* Active small intestinal inflammation
* Previous resection of distal small intestine
* Treatment with bile salt binding agents, ciclosporin or ciprofloxacin
* Diarrhoea (from any cause) at study initiation
* hypersensitivity to bile acids or any excipient of the formulation
* Life expectancy less than 6 months
What they're measuring
1
To assess tolerability to oral ursodeoxycholic acid